NCT07104266 - Triple Negative Breast Cancer and Celecoxib. Pilot Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

August 4, 2028

Study Completion Date

August 4, 2032

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG

Celecoxib (Celebrex)

The participants will take one capsule celecoxib (100 mg) or placebo after breakfast and one after supper, starting 7 days before radiotherapy and ending 14 days after radiotherapy.

DRUG

Placebo

Participants will take one capsule of placebo after breakfast and one after supper, starting 7 days before radiotherapy and ending 14 days after radiotherapy.

Trial Locations (1)

J1H 5N4

RECRUITING

Faculty of medicine and health sciences, Sherbrooke

All Listed Sponsors

lead

Université de Sherbrooke

OTHER